Clinical Study

Nrg-Gy005-A Randomized Phase II/III Study Of The Combination Of Cediranib And Olaparib Compared To Cediranib Or Olaparib Alone, Or Standard Of Care Chemotherapy In Women With Recurrent Platinum-Resistant Or -Refractory Ovarian, Fallopian Tube, Or Primary

Posted Date: Oct 1, 2019

  • Investigator: Eric Eisenhauer
  • Specialties: Cancer, Gynecologic Oncology, Gynecology, Oncology, Ovarian Cancer
  • Type of Study: Drug

The goal of this study is To assess the efficacy and identify (in)active arm(s) of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by PFS in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer.


To Be Eligible: Diagnosed With Ovarian, Peritoneal, Or Fallopian Tube Cancer, Controlled Blood Pressure, >18 Years Of Age, No Prior Use Of Parp Inhibitors, No Uncontrolled Or Active Illness, Nonpregnant/Nonbreastfeeding


Ovarian Cancer, Peritoneal, Gynecology

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.